For a complete press release follow the link https://dev.isofolmedical.com/ipo
For additional information, please contact:
Anders Rabbe, CEO, Isofol, Mob: +46 70 764 65 00, Email: firstname.lastname@example.org
Jan-Eric Österlund, Executive Chairman of the Board, Isofol, Mob: +44 77 853 68 155, Email: email@example.com
About Isofol Medical AB (publ)
Isofol is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Isofol aims to replace the existing folate-based compounds leucovorin and levoleucovorin, which today are considered the standard treatment within these indications. Through an exclusive license agreement, Isofol Medical holds all rights to commercialising Modufolin® globally for cancer treatment with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany.